Last reviewed · How we verify

NCT02853812: ACCELA

Tinnitus Related Cerebral Activities

Terminated NA Last updated 28 December 2021
What this trial tests

NA trial testing Functional brain MRI in Tinnitus in 24 participants. Terminated before completion.

Timeline
5 February 2013
Primary endpoint
27 August 2015
27 August 2015

Quick facts

Lead sponsorUniversity Hospital, Montpellier
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment24
Start date5 February 2013
Primary completion27 August 2015
Estimated completion27 August 2015

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Montpellier

Who can join

Adults 18 to 70, any sex, with Tinnitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The proposed research is to identify the brain areas activated or deactivated by tinnitus in humans. The identification of these areas is expected to be able to treat tinnitus refractory to traditional therapies by methods of brain stimulation. Furthermore, this technique would be very useful to verify the effectiveness of any treatment to relieve tinnitus. The brain activation measured during fMRI will be performed in a position of rest, after inhibition of tinnitus, and after application of a sound that does not inhibit tinnitus. This comparison will identify specific brain areas activated or deactivated by tinnitus.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Tinnitus

Currently open trials in the same condition.

Other University Hospital, Montpellier trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02853812.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing